Title: Evaluation of fibrinogen level as a non conventional risk factor in patients of acute MI in north Indian patients
Authors: Dr Rajkumar Verma, Dr Mridul Chaturvedi, Dr Sachu Sabu, Dr Kushal Pal
DOI: https://dx.doi.org/10.18535/jmscr/v8i3.107
Abstract
Introduction
The conventional risk factors, like age, smoking, hyperlipidaemia do not explain all the mortality and morbidity due to coronary artery disease[1]. Recently non-conventional factors like plasma fibrinogen, C reactive protein, homocysteine have been recognized as independent risk factors to explain the present epidemic of coronary artery disease in Indian patients.[2] Serum fibrinogen is a newer independent risk factor for CAD[3]. Fibrinogen increases the blood viscosity and plays a key role in thrombosis, both of which promotes coronary artery atherosclerosis.
In cardiovascular disease, fibrinogen has been mainly considered as being involved in thrombotic occlusion and hence in the final stage of atherosclerosis[5]. Fibrinogen is a well-known acute phase protein and the most abundant coagulation factor in the blood. As a short half-life protein and indicator of procoagulant state which was swiftly consumptions, circulating Fib was not only involved in acute phase of acute coronary syndrome (ACS) but also participated in chronic inflammatory response, which could accelerate the progress of atherosclerosis, and subsequently lead to the development of clinical CAD.[6]
Experimental studies have also suggested that fibrinogen and fibrin degradation products may increase coronary plaque vulnerability by stimulating coagulation, platelet aggregation, and vascular endothelial dysfunction.[7] However a number of investigators have suggested that fibrinogen may play a more active role in the development and progression of atherosclerotic plaque.[8] Smooth muscle cell proliferation stimulated by fibrinogen, suggests that fibrinogen is involved in the earliest stage of plaque formation.[9]
References
1. Iftikhar J.Kullo and Christie M.Ballantyne. Conditional Risk Factors for Atherosclerosis. Mayo Clinic Proceedings 2005; 80: 219-230.
2. Harish RB, Govindaraju V, Manjunath CN. Risk prediction-Homocysteine in Coronary Heart Disease. Indian J Clin Biochem. 2007 Mar;22(1):18-21.
3. Knopp RH. Risk factors for coronary artery disease inwomen. Am J Cariol 2002; 89 (S12A): 28E-34E.
4. Assmann G, Cullen P and Schulte H. Simple scoring calculating the risk of acute coronary events based on 10 year follow-up of the Prospective Cardiovascular Munter (PROCAM) study. Circulation 2002; 105: 310-315.
5. Binder CJ, et al: Innate and acquired immunity in atherogenesis. Nat. Med.2002; 8: 12118.
6. M. Loukas, M. Dabrowski, T. Wagner, E. Walczak, A. Witkowski, and W. Ruzyłło, “Fibrinogen and smooth muscle cell detection in atherosclerotic plaques from stable and unstable angina -an immunohistochemical study,” Medical Science Monitor, vol. 8, no. 4, pp. BR144–BR148, 2002
7. Ndrepepa G, Braun S, King L, Fusaro M, Keta D, Cassese S, Tada T, Schömig A, Kastrati A. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2013 Mar 15;111(6):804-10.
8. Pearson TA, Menash GA, Alexender RW, et al: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: Circulation. 2003; 107: 499-511.
9. Peter Libby, Paul M.Ridker, Attilio Maseri: Inflammation and Atherosclerosis: Circulation. 2002; 105: 1135.
10. Mohan, V., Deepa, R., Shanthirani, S. and Premalatha, G., J. Am. Coll. Cardiol., 2001, 38, 682-687.
11. Khaw, K. T., Wareham, N., Luben, R., Bingham, S., Oakes, S., Welch, A. and Day, N., Br. Med, J., 2001, 322, 15-18.
12. Ernst E. The role of fibrinogen as a cardipovascular risk factor. Atherosclerosis. 1993; 100:1-12.
13. Mach F et al: C-reactive protein as a marker for acute coronary syndrome. Eur. Heart J. 1997 Dec; 18(12) : 1897-902.
14. Gao XY, Zhou BY, Zhang MZ, et al. Association between fibrinogen level and the severity of coronary stenosis in 418 male patients with myocardial infarction younger than 35 years old. Oncotarget. 2017;8(46):81361–81368. Published 2017 Jun 20. doi:10.18632/oncotarget.18578
15. Zhang Y, Zhu CG, Guo YL, Xu RX, LiS, Dong Q, Li JJ. Higher fibrinogen level is independently linked with the presence and severity of new-onset coronary atherosclerosis among Han Chinese population. PLoS One. 2014 Nov 26;9(11)
16. Papageorgiou N, Briasoulis A, Hatzis G, Androulakis E, Kozanitou M, Miliou A, Charakida M, Zacharia E, Papaioannou S, Paroutoglou I, Siasos G, Pallantza Z, Tousoulis D ,Coronary Artery Atheroscle-rosis in Hypertensive Patients: The Role of Fibrinogen Genetic Variability. Rev Esp Cardiol (Engl Ed). 2017 Jan;70(1):34-4.
17. Ernst E. The role of fibrinogen as a cardiovascular risk factor. Atherosclerosis. 1993 Apr;100(1):1-12
18. Song B, Shu Y, Xu YN, Fu P. Plasma fibrinogen lever and risk of coronary heartdisease among Chinese population: a systematic review and meta-analysis. Int J Clin Exp Med. 2015 Aug 15;8(8):13195-202.
19. Li T, Wang F, Peng R, Pei S, Hou Z, Lu B, Cong X, Chen X. Sex-related differences in the association between plasma fibrinogen and non-calcified or mixed coronary atherosclerotic plaques. Biol Sex Differ. 2018 Dec 5;9(1):51
20. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation. 1995 Jul 1;92(1):31-8.
21. Boda Z. Fibrinogen as an independent cardiovascular risk factor and the question of treatment with fibrinogen-lowering drugs. Orv Hetil. 1997 Sep 28;138(39): 2455-60. Review.